Cost effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole for the treatment of post-menopausal women with hormone receptor-positive (HR+) …
G Suri, R Mistry, KC Young, R Hettle… - Value in …, 2017 - valueinhealthjournal.com
Objectives To assess the cost effectiveness of ribociclib+ letrozole (Rib) versus palbociclib+
letrozole (Pal) for the first-line treatment of post-menopausal women with HR+/HER2-
advanced or metastatic breast cancer using a US third-party payer perspective
(commercial). Methods The lifetime costs and effectiveness of treatment were simulated
using a cohort-based, three-state (progression-free [PF], progressed disease [PD], and
death) partition survival model with a one-month cycle length. Clinical data were derived …
letrozole (Pal) for the first-line treatment of post-menopausal women with HR+/HER2-
advanced or metastatic breast cancer using a US third-party payer perspective
(commercial). Methods The lifetime costs and effectiveness of treatment were simulated
using a cohort-based, three-state (progression-free [PF], progressed disease [PD], and
death) partition survival model with a one-month cycle length. Clinical data were derived …
以上显示的是最相近的搜索结果。 查看全部搜索结果